Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 79.8%

Neg 79.8% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $27 to $26.